Delanzomib

Description: Delanzomib (CEP-18770) is an orally active inhibitor of the chymotrypsin-like activity of proteasome (IC50: 3.8 nM). It only marginally inhibits the tryptic and peptidylglutamyl activities of the proteosome. Target: Apoptosis, Proteasome, NF-kappaB. Smiles: CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O. References: Piva R,et al. Blood. 2008,111(5),2765-2775.